Showing 2644 results
- Key Release /Holzkirchen, May 2, 2018 - Sandoz, a Novartis division, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the Biologics Licensing…
- Media Release /Kymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of data cut-off, indicating sustainability of response[1] Kymriah is the only…
- Key Release /Basel, May 1, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") applicable to…
- Media Release /Tafinlar + Mekinist is the first oral targeted adjuvant combination therapy to demonstrate significant clinical benefit in patients with a BRAF V600 mutation, following complete surgical resection…
- Media Release /Patients identified for brolucizumab 12-week treatment interval in Phase III HAWK and HARRIER trials had an 87% and 83% probability of successfully continuing on a 12-week interval through week…
- Media Release /Basel, March 28, 2018 - Novartis will present new data from the HAWK and HARRIER Phase III trials at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting,…
- Key Release /Price reflects an attractive value to Novartis Proceeds to be used according to capital allocation priorities, including bolt-on acquisitions Sale of JV in a non-core segment in best long-term…
- Key Release /Preis stellt für Novartis einen attraktiven Wert dar Verkaufserlös wird in Übereinstimmung mit den Prioritäten für die Kapitalallokation verwendet, einschliesslich für Bolt-on-Akquisitionen Verkauf…
- Media Release /Sandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology Positive opinion is based on a…
- Media Release /EXPAND shows oral siponimod (BAF312) is the first potential therapy to meaningfully delay disability progression in typical secondary progressive MS (SPMS) patients Results demonstrate…
Pagination
- ‹ Previous page
- 1
- …
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- …
- 265
- › Next page